HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Brii Biosciences / Equity Capital Markets

On April 8, 2021, <a href="https://www.smartkarma.com/entities/brii-biosciences" target="_blank" data-smartkarma-citation="entities:33014:1" rel="noopener">Brii Biosciences (1621985D US) </a>submitted its listing application to the main board of the Hong Kong Stock Exchange. Since June 2018, the Company has raised several rounds of funding with approximately US$414 million in total. In March of this year, Brii completed a US$155 million Series C financing with a post-financing valuation of US$1.455 billion. The founding investors include Boyu, 6 Dimensions, ARCH, Sequoia China, Yunfeng and BluePool, which are all well-known healthcare and biotech funds. Compared with the financing of tumor immunity and cell therapy projects, it is less common for large-scale financing in the field of anti-infection. So what makes the Company so special that it attracts so many star investors? This insight mainly analyzed the key product candidates and related concerns.

On April 8, 2021, Brii Biosciences (1621985D US) submitted its listing application to the main board of the Hong Kong Stock Exchange. Since June 2018, the Company has raised several rounds of funding with approximately US$414 million in total. In March of this year, Brii completed a US$155 million Series C financing with a post-financing valuation of US$1.455 billion. The founding investors include Boyu, 6 Dimensions, ARCH, Sequoia China, Yunfeng and BluePool, which are all well-known healthcare and biotech funds. Compared with the financing of tumor immunity and cell therapy projects, it is less common for large-scale financing in the field of anti-infection. So what makes the Company so special that it attracts so many star investors? This insight mainly analyzed the key product candidates and related concerns.

Pre-IPO Brii Biosciences - Insights on Pipeline and Related Concerns

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Tasly Biopharmaceuticals / Equity Capital Markets

Tasly Biopharm, a biologics R&amp;D platform spin-off from A-share listed <a href="https://www.smartkarma.com/entities/tasly-pharmaceutical-group-co" target="_blank" data-smartkarma-citation="entities:9569:1" rel="noopener">Tasly Pharmaceutical Group (600535 CH)</a>, is looking to raise up to USD 1 bn via a listing in Hong Kong.
In this insight, we will cover the company background, the key products that have reached the clinical trial stage, and the company's shareholders and investors.
We think the company has demonstrated its capability of completing R&amp;D and commercializing a product. The future growth from pro-UK series of drugs is visible as the clinical trials progress. But at the same time, we don't see opportunities for exponential growth from blockbuster products.

Tasly Biopharm, a biologics R&amp;D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1 bn via a listing in Hong Kong.
In this insight, we will cover the company background, the key products that have reached the clinical trial stage, and the company's shareholders and investors.
We think the company has demonstrated its capability of completing R&amp;D and commercializing a product. The future growth from pro-UK series of drugs is visible as the clinical trials progress. But at the same time, we don't see opportunities for exponential growth from blockbuster products.

Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters

Tasly Biopharmaceuticals (TASLY HK)

Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters

Tasly Biopharm, a biologics R&D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1...

Ke Yan, CFA, FRM

Pre-IPO Brii Biosciences - Insights on Pipeline and Related Concerns

This insight mainly analyzed the core product candidates of Brii Biosciences in the pipeline (HBV, COVID-19 products and others), the competitive...

Xinyao (Criss) Wang

Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters

Tasly Biopharm, a biologics R&D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1...

Ke Yan, CFA, FRM